-
In vitro anticancer activity of Hirudinaria manillensis methanolic extract and its validation using in silico molecular docking approach Med. Oncol. (IF 3.4) Pub Date : 2024-03-15 P. Zeebul Trinita Shannan, Susan G. Suganya, E. Angel Jemima, M. Ramesh
-
Role of interferon-induced transmembrane protein family in cancer progression: a special focus on pancreatic cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-12 Peipei Wang, Yan Pan, Yu Zhang, Congliang Chen, Junmei Hu, Xia Wang
-
High expression of CD9 and Epidermal Growth Factor Receptor promotes the development of tongue cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-12
Abstract Tongue cancer is distinguished by aggressive behavior, a high risk of recurrence, lymph, and distant metastases. Hypoxia-Induced Factor 1 α functions as a CD9 transcription factor. CD9 is a transmembrane protein that may be found on the cell membrane. It can modulate the expression of the Epidermal Growth Factor Receptor (EGFR) pathway. ELISA was used to measure serum CD9, p-EGFR, and p-Akt
-
The cytotoxic effects of prazosin, chlorpromazine, and haloperidol on hepatocellular carcinoma and immortalized non-tumor liver cells Med. Oncol. (IF 3.4) Pub Date : 2024-03-12
Abstract Liver cancer annually accounts for over 800,000 cases and 700,000 deaths worldwide. Hepatocellular carcinoma is responsible for over 80% of liver cancer cases. Due to ineffective treatment options and limited surgical interventions, hepatocellular carcinoma is notoriously difficult to treat. Nonetheless, drugs utilized for other medical conditions, such as the antihypertensive medication prazosin
-
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator Med. Oncol. (IF 3.4) Pub Date : 2024-03-05 Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
-
Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2024-03-04 Aydemir ASDEMİR, Aykut ÖZGÜR
-
An effective treatment approach of liposomally encapsulated metformin in colon cancer Med. Oncol. (IF 3.4) Pub Date : 2024-02-28
Abstract Metformin is a drug that is widely used in the treatment of type-2 diabetes and its anticarcinogenic effect has been detected in many studies since the 2000s. Metformin has a short half-life and poor biocompatibility, which limits the activity of the drug. As a solution to this situation, our study aimed to increase the anticarcinogenic effects and reduce the side effects of metformin in colon
-
Exploring the Potential of Essential Oil from Plectranthus amboinicus Leaves against Breast Cancer: In vitro and In silico Analysis Med. Oncol. (IF 3.4) Pub Date : 2024-02-24 Khushi Gupta, Pranay Gautre, Avadh Biharee, Yogesh Singh, Umesh Kumar Patil, Shashank Kumar, Suresh Thareja
-
Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Ian M. Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Thuy Ho, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant, Keri R. Maher
-
TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Yu-Ting Yin, Lu Shi, Chun Wu, Mei-Yin Zhang, Jia-Xin Li, Yu-Feng Zhou, Shuo-Cheng Wang, Hui-Yun Wang, Shi-Juan Mai
-
Estrogen-related receptor alpha (ERRα) promotes the migration, invasion and angiogenesis of breast cancer stem cell-like cells Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Kartik Muduli, Jagannath Pradhan, Monica Prusty, Archana Priyadarshini Samal, K Sony Reddy, Selvakumar Elangovan
-
Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS) Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Alexander S. Taylor, Rahul Mannan, Liron Pantanowitz, Arul M. Chinnaiyan, Saravana M. Dhanasekaran, Steven Hrycaj, Xuhong Cao, May P. Chan, David Lucas, Xiao-Ming Wang, Rohit Mehra
-
Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity Med. Oncol. (IF 3.4) Pub Date : 2024-02-21 Qiang You, Rong Li, Jia Yao, Ying-Cai Zhang, Xin Sui, Cui-Cui Xiao, Jie-Bin Zhang, Jia-Qi Xiao, Hai-Tian Chen, Hua Li, Jian Zhang, Jun Zheng, Yang Yang
-
Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target Med. Oncol. (IF 3.4) Pub Date : 2024-02-20
Abstract Urothelial Carcinoma of Bladder is complex disease with high mortality and recurrence rates. Current standard regimes have exhibited anti-tumor activity but still, a proportion of patients are non-responsive or in-eligible to receive such treatments. Immune checkpoints have emerged as potential class of therapeutics to be tested in UCB patients. Clinical trials targeting PD-1/PD-L1 axis have
-
Advancements in biosensors for cancer detection: revolutionizing diagnostics Med. Oncol. (IF 3.4) Pub Date : 2024-02-19 Syed Khalid Mustafa, Mohd. Farhan Khan, Mehak Sagheer, Deepak Kumar, Sadanand Pandey
-
CRP inhibits the osteoblastic differentiation of OPCs via the up-regulation of primary cilia and repression of the Hedgehog signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2024-02-12 Jie Xu, Xiangmei Wu, Huifang Zhu, Yinghua Zhu, Kailong Du, Xiaoyan Deng, Changdong Wang
-
Selective targeting or reprogramming of intra-tumoral Tregs Med. Oncol. (IF 3.4) Pub Date : 2024-02-11 Keywan Mortezaee
-
The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study Med. Oncol. (IF 3.4) Pub Date : 2024-02-10 Abbas Alalikhan, Safieh Ebrahimi, Ali Aliee, Farshad Mirzavi, Seyed Isaac Hashemy
-
A therapeutical insight into the correlation between circRNAs and signaling pathways involved in cancer pathogenesis Med. Oncol. (IF 3.4) Pub Date : 2024-02-04 Raed Obaid Saleh, Sulieman Ibraheem Shelash Al-Hawary, Saade Abdalkareem Jasim, Dmitry Olegovich Bokov, Ahmed Hjazi, Khulood H. Oudaha, Mohammed Jawad Alnajar, Sally Salih Jumaa, Ahmed Alawadi, Ali Alsalamy
-
Regulation of the P53 tumor suppressor gene and the Mcl-2 oncogene expression by an active herbal component delivered through a smart thermo-pH-sensitive PLGA carrier to improve Osteosarcoma treatment Med. Oncol. (IF 3.4) Pub Date : 2024-01-30 Parinaz Akbari, Mohammad Taebpour, Milad Akhlaghi, Shaimaa Hamid Hasan, Shayesteh Shahriyari, Mahdieh Parsaeian, Bibi Fatemeh Haghirosadat, Abbas Rahdar, Sadanand Pandey
-
Unlocking the ‘ova’-coming power: immunotherapy’s role in shaping the future of ovarian cancer treatment Med. Oncol. (IF 3.4) Pub Date : 2024-01-29 Nathan A. Haines, Mia G. Fowler, Benjamin G. Zeh, Carter B. Kriete, Qian Bai, Mark R. Wakefield, Yujiang Fang
-
Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1 Med. Oncol. (IF 3.4) Pub Date : 2024-01-28 Jackie L. Ha, Erin Kaser, Tianyun Guan, Trenton G. Mayberry, Luke A. Smith, Kyle D’mello, Qian Bai, Mark R. Wakefield, Lijun Dong, Yujiang Fang
-
Pyroptosis in cancer treatment and prevention: the role of natural products and their bioactive compounds Med. Oncol. (IF 3.4) Pub Date : 2024-01-28
Abstract Targeting programmed cell death (PCD) has been emerging as a promising therapeutic strategy in cancer. Pyroptosis, as a type of PCDs, leads to the cleavage of the gasdermin family and the secretion of pro-inflammatory factors. Gasdermin D (GSDMD) and gasdermin E (GSDME) are the two main executors of pyroptosis. Pyroptosis in tumor and immune cells is essential for tumor progression. Natural
-
Synergistic inhibitory actions of resveratrol, epigallocatechin-3-gallate, and diallyl trisulfide against skin cancer cell line A431 through mitochondrial caspase dependent pathway: a combinational drug approach Med. Oncol. (IF 3.4) Pub Date : 2024-01-27 Gobika Arumugam, Sangilimuthu Alagar Yadav
-
C-5401331 identified as a novel T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) inhibitor to control acute myeloid leukemia (AML) cell proliferation Med. Oncol. (IF 3.4) Pub Date : 2024-01-24 Mesfer Al Shahrani, Reem M. Gahtani, Mohammed Makkawi
-
Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study Med. Oncol. (IF 3.4) Pub Date : 2024-01-23 Fawziya A. R. Ibrahim, Neveen A. Hussein, Aisha Y. M. Soliman, Thanaa I. shalaby, Mona M. Rashad, Noura A. Matar, Tarek S. El-Sewedy
-
A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia Med. Oncol. (IF 3.4) Pub Date : 2024-01-23 Ali Salehi
-
Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway Med. Oncol. (IF 3.4) Pub Date : 2024-01-22 XueFeng Feng, Lin Yang, Xiaojun Liu, Menghan Liu, Lu Liu, Jing Liu, JianMin Luo
-
Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition Med. Oncol. (IF 3.4) Pub Date : 2024-01-18
Abstract The evolution of the complex immune system is equipped to defend against perilous intruders and concurrently negatively regulate the deleterious effect of immune-mediated inflammation caused by self and nonself antigens. Regulatory T-cells (Tregs) are specialized cells that minimize immune-mediated inflammation, but in malignancies, this feature has been exploited toward cancer progression
-
Gingerol and/or sorafenib attenuates the DAB-induced HCC and hepatic portal vein dilatation via ATG4/CASP3 and COIIV/COX-2/NF-κB expression Med. Oncol. (IF 3.4) Pub Date : 2024-01-16 Afrah Fatthi Salama, Ali H. El-Far, Esraa Ali Anbar, Sabry Ali El-Naggar, Rami M. Elshazli, Alaa Elmetwalli
-
Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells Med. Oncol. (IF 3.4) Pub Date : 2024-01-17 Kantasorn Horpratraporn, Patthamapon Adchariyasakulchai, Panot Sainamthip, Wannarasmi Ketchart
-
Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mTOR pathway in triple-negative breast cancer cells Med. Oncol. (IF 3.4) Pub Date : 2024-01-13 Preeti Sharma, Shubhra Chaturvedi, Mohammad Ahmed Khan, Yogesh Rai, Anant Narayan Bhatt, Abul Kalam Najmi, Mohd. Akhtar, Anil Kumar Mishra
-
Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels Med. Oncol. (IF 3.4) Pub Date : 2024-01-12 Manvi Bansal, Sana Ansari, Malkhey Verma
-
SLFN11 promotes clear cell renal cell carcinoma progression via the PI3K/AKT signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2024-01-11 He-Xi Wang, Zhi-Peng Zhao, Xiao-Yi Du, Sen-Lin Peng, Hao-Yu Xu, Wei Tang, Lei Yang
-
A comprehensive review on the applications of ferrite nanoparticles in the diagnosis and treatment of breast cancer Med. Oncol. (IF 3.4) Pub Date : 2024-01-10 Muhammad Furqan Akhtar, Aysha Afzaal, Ammara Saleem, Amna Roheel, Muhammad Imran Khan, Mohd Imran
-
lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways Med. Oncol. (IF 3.4) Pub Date : 2024-01-09 Raed Obaid Saleh, Mushtak T. S. Al-Ouqaili, Eyhab Ali, Sharif Alhajlah, Anaheed Hussein Kareem, Maha Noori Shakir, Mohammed Qasim Alasheqi, Yasser Fakri Mustafa, Ahmed Alawadi, Ali Alsaalamy
-
Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies Med. Oncol. (IF 3.4) Pub Date : 2024-01-09 Neha R. Raghani, Mehul R. Chorawala, Mayuresh Mahadik, Rakesh B. Patel, Bhupendra G. Prajapati, Priyajeet S. Parekh
-
Arsenic-induced prostate cancer: an enigma Med. Oncol. (IF 3.4) Pub Date : 2024-01-06 Anirban Goutam Mukherjee, Abilash Valsala Gopalakrishnan
-
Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation Med. Oncol. (IF 3.4) Pub Date : 2024-01-06 Saptarshi Sinha, Subarno Paul, Sushree Subhadra Acharya, Chinmay Das, Somya Ranjan Dash, Subhasmita Bhal, Rajalaxmi Pradhan, Biswajit Das, Chanakya Nath Kundu
-
Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma Med. Oncol. (IF 3.4) Pub Date : 2024-01-04 Ping Lei, Liting Yu, Xiaoli Sun, Junmei Hao, Wenning Shi, Haojie Sun, Xiangji Guo, Xikang Jia, Tianli Liu, Dao-Lai Zhang, Lianqin Li, Hongmei Wang, Cong Xu
-
Genipin inhibits proliferation of gastric cancer cells by inducing ferroptosis: an integrated study of network pharmacology and bioinformatics study Med. Oncol. (IF 3.4) Pub Date : 2024-01-04 Yalu Mi, Hui Shan, Bo Wang, Huidi Tang, Jihui Jia, Xijian Liu, Qing Yang
-
Utility of MRI in detection of PET-CT proven local recurrence of pancreatic adenocarcinoma after surgery Med. Oncol. (IF 3.4) Pub Date : 2024-01-04 D. Saponjski, A. Djuric-Stefanovic, M. Mitrovic Jovanovic, A. Jankovic, J. Kovac, S. Milosevic, K. Stosic, J. Pantovic, J. Petrovic, S. Kmezic, D. Radenkovic, D. Sobic Saranovic
Abstract The aim of this prospective study was to investigate the accuracy and inter-observer reliability of MRI in detection of local recurrence (LR) of pancreatic adenocarcinoma (PAC) after surgery, which was proved by PET-CT and access correlation between functional MRI and PET parameters. Forty-five patients who underwent PET-CT and MRI for follow-up purposes after radical operation of PAC were
-
Phytometabolites as modulators of breast cancer: a comprehensive review of mechanistic insights Med. Oncol. (IF 3.4) Pub Date : 2024-01-03 Priyanka Sharma, Khushi Gupta, Sumit Kumar Khandai, Sonia Malik, Suresh Thareja
-
Modulation of autophagy and apoptosis can contribute to the anticancer effect of Abemaciclib/Celecoxib combination in colon cancer cells Med. Oncol. (IF 3.4) Pub Date : 2024-01-03 Dalia Mohamed Elsayed Alian, Maged W. Helmy, Medhat Haroun, Nermine Moussa
-
Population-based high-dimensional analyses identify multiple intrinsic characters for cancer vaccines against lung squamous cell carcinoma Med. Oncol. (IF 3.4) Pub Date : 2024-01-03 Longjin Zeng, Lingchen Li, Xingyun Liao, Lincheng Zhang, Chenrui Yin, Xiewan Chen, Jianguo Sun
-
Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2024-01-03 Donglin Sun, Jing Guo, Weifei Liang, Yangxiao Chen, Shuqi Wei, Ai Li, Li Wang, Xiangqiu Chen
-
COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers Med. Oncol. (IF 3.4) Pub Date : 2024-01-02
Abstract Cyclooxygenase (COX) enzymes are pivotal in inflammation and cancer development. COX-2, in particular, has been implicated in tumor growth, angiogenesis, and immune evasion. Recently, COX-2 inhibitors have arisen as potential therapeutic agents in cancer treatment. In addition, combining COX inhibitors with other treatment modalities has demonstrated the potential to improve therapeutic efficacy
-
In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma Med. Oncol. (IF 3.4) Pub Date : 2023-12-28 Abas Sezer, Lejla Mahmutović, Betül Akçeşme
-
Identification of hub genes to determine drug-disease correlation in breast carcinomas Med. Oncol. (IF 3.4) Pub Date : 2023-12-28 Chiranjib Bhowmick, Motiur Rahaman, Shatarupa Bhattacharya, Mandrita Mukherjee, Nishant Chakravorty, Pranab Kumar Dutta, Manjunatha Mahadevappa
-
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview Med. Oncol. (IF 3.4) Pub Date : 2023-12-29 Priyatharcini Kejamurthy, K. T. Ramya Devi
-
PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative “triplet” for oligometastatic hormone sensitive prostate cancer patients Med. Oncol. (IF 3.4) Pub Date : 2023-12-29 Giulio Francolini, Angelo Porreca, Gaetano Facchini, Daniele Santini, Alessio Bruni, Nicola Simoni, Marco Trovò, Mattia Falchetto Osti, Giuseppe Fornarini, Michele Sisani, Vanessa Di Cataldo, Beatrice Detti, Pietro Garlatti, Niccolò Bertini, Sergio Serni, Andrea Minervini, Lorenzo Livi
-
Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer Med. Oncol. (IF 3.4) Pub Date : 2023-12-29 Alaa Elmetwalli, Aly Nageh, Amany I. Youssef, Magda Youssef, Mohamed Abd El-Rahman Ahmed, Ahmed E. Noreldin, Tarek El-Sewedy
-
Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs Med. Oncol. (IF 3.4) Pub Date : 2023-12-27 Xingyu Jiang, Sumeng Wang, Qi Liang, Yiqian Liu, Lingxiang Liu
-
USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells Med. Oncol. (IF 3.4) Pub Date : 2023-12-27 Sicong Hou, Tiantian Zhao, Bin Deng, Caimin Li, Wenqian Li, Haifeng Huang, Qinglei Hang
-
Gastrodin inhibits prostate cancer proliferation by targeting canonical Wnt/β-catenin signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2023-12-27
Abstract Prostate cancer is an epithelial malignant tumor occurring in the prostate and is the most common malignant tumor in the male genitourinary system. In recent years, the incidence of prostate cancer in China has shown a trend of sudden increase. The search for new and effective drugs to treat prostate cancer is therefore extremely important.The canonical Wnt/β-catenin signaling pathway has
-
Intestinal epithelial SNAI1 promotes the occurrence of colorectal cancer by enhancing EMT and Wnt/β-catenin signaling Med. Oncol. (IF 3.4) Pub Date : 2023-12-27 Furong Qing, Junxia Xue, Lina Sui, Qiuxiang Xiao, Tao Xie, Yayun Chen, Junyun Huang, Zhiping Liu
-
GNL3L promotes autophagy via regulating AMPK signaling in esophageal cancer cells Med. Oncol. (IF 3.4) Pub Date : 2023-12-26
Abstract Guanine nucleotide-binding protein-like 3-like (GNL3L), a conserved GTP-binding nucleolar protein, participates in regulating cell proliferation, and associates with tumorigenesis and poor prognosis in several kind of cancers. However, the role of GNL3L in modulating autophagy remains unclear. Here, we verified that GNL3L was higher expressed in esophageal cancer (ESCA) biopsies than that
-
Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells Med. Oncol. (IF 3.4) Pub Date : 2023-12-26 Merve Şansaçar, Helin Sağır, Emel Başak Gencer Akçok
-
The emerging role of breast cancer derived extracellular vesicles-mediated intercellular communication in ovarian cancer progression and metastasis Med. Oncol. (IF 3.4) Pub Date : 2023-12-26 Melis Rahime Yıldırım, Oğuz Kaan Kırbaş, Hüseyin Abdik, Fikrettin Şahin, Ezgi Avşar Abdik
-
Association of Wiskott-Aldrich syndrome protein (WASp) in epigenetic regulation of B cell differentiation in non-small-cell lung cancer (NSCLC) Med. Oncol. (IF 3.4) Pub Date : 2023-12-25 Nikhil Chandnani, Ayush Mandal, Ishika Gupta, Oishi Mukherjee, Sudeshna Rakshit, Geetha Shanmugam, Melvin George, Koustav Sarkar